Assessment of efficy and safety of everolimus in Japanese patients with mRCC

Assessment of efficy and safety of everolimus in Japanese patients with mRCC - Assessment of efficy and safety of everolimus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009620

Enrollment

200

Registered

2013-01-07

Start date

2013-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Suitable for everolimus treatment

Exclusion criteria

Exclusion criteria: Unsuitable for everolimus treatment

Design outcomes

Primary

Measure	Time frame
PFS, AEs	—

Countries

Japan

Contacts

Public ContactRyuichi Mizuno M.D.

Keio university, school of medicine Department of Urology

mizunor@z7.keio.jp

Outcome results